Estrella Immunopharma, Inc. received a written notification from Nasdaq on September 1, 2026, indicating non-compliance with the minimum market value of listed securities (MVLS) requirement due to an MVLS below $35,000,000 for 30 consecutive business days ending August 31, 2026. The company also fails alternative standards regarding stockholders' equity and net income. Nasdaq granted a compliance period of 180 calendar days until March 1, 2027, to regain compliance by achieving an MVLS of at least $35,000,000 for ten consecutive business days. Trading will continue under the symbol ESLA during this period, but failure to comply may result in delisting proceedings and a potential appeal process. Estrella Immunopharma operates in the biotechnology industry, focusing on immunopharmaceutical drug development.